2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1811 10 year event free status identifies durable disease control in adolescents and young adults (AYA) with follicular lymphoma (FL) from the university of Iowa/Mayo Clinic SPORE molecular epidemiology resource (MER)

Jonathan R Day, PharmD, MD, Melissa Larson, MS2, Laura C Magnano Mayer, MD3, Eric Mou, MD4, Rebecca L King, MD5, Mazie Tsang, MD, MAS, MS6, Arushi Khurana, MBBS7, Urshila Durani, MD, MPH8, Patrizia Mondello, MD, PhD9, Jose C Villasboas, MD10, Aditya Ravindra, MD11, Gita Thanarajasingam, MD12, Carrie Thompson, MD13, Sergei Syrbu, MD14, Andrew L. Feldman, MD15, Allison C Rosenthal, DO16, Umar Farooq, MD17, Philippe Armand, MD18, Stephen Maxted Ansell, MD, PhD19, Thomas Witzig, MD20, Thomas M. Habermann, MD21, James R. Cerhan, MD, PhD22, Brian K Link, MD23, Yucai Wang, MD, PhD24, Matthew E. Maurer, ScD25
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 University of Iowa, Iowa City, Iowa, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Phoenix, Arizona, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 University of Iowa, Iowa City, Iowa, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 University of Iowa, Iowa City, Iowa, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Phoenix, Arizona, United States
17 University of Iowa, Iowa City, Iowa, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 University of Iowa, Iowa City, Iowa, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States

Introduction: Follicular lymphoma (FL) is uncommon in adolescents and young adults (AYA), and data on long-term outcomes in this population is needed. Recent data from our group and S0016 suggest that 40% of immunochemotherapy (IC) treated patients may be cured or have long term durable remissions. The importance of long-term prognosis is more important in the AYA population as the goal is to reduce long term toxicity. Additionally distinguishing classic FL and pediatric-type FL, characterized by unique clinicopathologic features, lower stage (I-II), restriction to lymph nodes of the head/neck, and an excellent prognosis (>95% survival with minimal therapy). We evaluated long-term outcomes of AYA patients with classic FL enrolled in University of Iowa/Mayo Clinic MER.

Methods: Pts age 18-39 with biopsy-proven FL 1-3A at diagnosis (dx) prospectively enrolled within 9 months of dx from 2002-2015 in the MER were included. Cases were reviewed by a hematologist and hematopathologist to exclude pediatric-type vs classic FL. Outcomes of interest were OS, lymphoma specific survival (LSS) (time from diagnosis to lymphoma death), event-free survival (EFS) (time from diagnosis to progression, treatment after observation, retreatment, histologic transformation (HT), or death), HT, and cause of death. HT defined as subsequent biopsy-proven FL 3B, diffuse large B cell lymphoma, or high-grade B cell lymphoma or clinical transformation. Analyses used the Kaplan-Meier method; cause of death used a competing risk approach. First events were also analyzed to separate out deaths from progression/retreatment/transformation (lymphoma events), lymphoma death (LD), non-lymphoma death (non-LD). Based on prior MER analysis, a landmark analysis at 10 years was conducted in pts who were event free and alive at 10 yrs with observed follow up through 10 yrs.

Results: 79 pts age 18-39 with FL 1-3A were enrolled in the MER from 2002-2015. Median age at dx was 35 yrs (IQR 31-37). Clinical characteristics were: 76% stage III/IV, 16% grade 3A, 3% ECOG PS 2-4, and 19% elevated LDH. Initial management was 28% observation (obs), 13% R-monotherapy (R-mono), 43% IC (47% R-CHOP, 29% R-CVP, 24% BR), 4% radiation only, and 10% others. FLIPI scores were 53% low, 38% intermediate (int), and 9% high; FLIPI24 risk categories were 50% low, 40% int, and 10% high. At a median follow-up of 14 yrs (IQR 10-18 yrs), 37 events (24 progression/treatment/retreatment, 6 HTs (5 biopsy proven, 1 clinical) and 7 deaths) were observed. Of deaths, 5 were lymphoma related (3 after HT), 2 non-lymphoma related.

EFS was 50% (95% CI 40-63) at 10 yrs and remain unchanged by 15 yrs. 15 yr EFS by initial treatments were 37% (95% CI 21-66) for obs, 56% (95% CI 31-100) for R-mono, and 56% (95% CI 41-77) for IC. At 15 yrs, 38% (95% CI 21-57) of observed pts remained untreated, and 56% (95% CI 3-80) of R-mono and 60% (95% CI 38-74) of IC-treated pts were free of progression, retreatment, or transformation.  

The incidence (95% CI) of HT was 7% (3-16%) at 10 yrs, and remained unchanged at 15 yrs, and 18 yrs. OS (95% CI) for the entire cohort was 92% (86-98%) at 10 yrs, 90% (83-97%) at 15 and 18 yrs. LSS was 95% (90-100%) at 10 yrs, 93% (87-99%) at 15 yrs and 18 yrs. The 15-yr cumulative risk of lymphoma related, and non-lymphoma related death were 7% (95%CI 3-16) and 3% (95%CI 1-12%), these were the same at 18 yrs.

In the landmark analysis of pts alive and event free with continued follow up at 10 yrs from dx (n=29), median age was 45 yrs (IQR 40-46) at landmark. There were no events, deaths, or transformations in the next 5 yrs (i.e. 15 yrs from dx) or 8 yrs (18 yrs from dx) for these patients.  

Conclusions: Among AYA patients with FL who after initial managment were alive and event free at 10 years, no subsequent events (progression/retreatment/HT or deaths) were observed demonstrating durable control. The landmark analysis is limited by small sample size including only patients who had continued follow up. Long term follow-up of AYA patients in the MER demonstrates excellent long-term survival (OS 90%, LSS of 93% at 15-18 years), yet EFS estimates of 50% at 10-15 years leave significant room for improvement regardless of initial management. These data establish that remaining event free for 10 years after diagnosis and initial management as a potentially clinically meaningful milestone of durable disease control.
Jonathan R Day, PharmD, MD: No relevant conflicts of interest to declare.